A Phase 1 Clinical Trial to Evaluate the Safety and the Pharmacokinetic Drug-Drug Interaction Between HUC2A-752-A and HUC2A-752-B in Healthy Adults

An Open-Label, Multiple-oral Dosing, Phase 1 Clinical Trial to Evaluate the Safety and the Pharmacokinetic Drug-Drug Interaction Between HUC2A-752-A and HUC2A-752-B in Healthy Adults

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07784621

Enrollment

Registered

2026-08-25

Start date

2026-10-01

Completion date

2027-02-01

Last updated

2026-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Brief summary

This study evaluates the pharmacokinetic drug-drug interactions of repeated co-administration of HUC2A-752-A and HUC2A-752-B compared to monotherapy of each agent in healthy adults

Detailed description

This randomized, open-label, 2-arm, 2-period, multiple-dose, phase 1 clinical trial evaluates the safety, tolerability, and pharmacokinetics of HUC2A-752 following repeated oral administration of HUC2A-752-A and HUC2A-752-B in healthy adult volunteers.

Interventions

DRUGLosartan (COZZAR®)

HUC2A-752-A

DRUGPitavastatin plus Ezetemibe

HUC2A-752-B

Study design

Allocation

RANDOMIZED

Intervention model

SEQUENTIAL

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

19 Years to 64 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy adult volunteers * Individuals with a body weight between 50.0 kg and 90.0 kg and a BMI between 18.5 kg/m² and 29.9 kg/m²

Exclusion criteria

* Individuals with a history or presence of clinically significant diseases of the following systems: hepatobiliary, renal, neurological, immunological, respiratory, gastrointestinal, endocrine, hematologic/oncologic, cardiovascular , musculoskeletal, urological, psychiatric, or sexual dysfunction. * Individuals with a history of gastrointestinal diseases or gastrointestinal surgeries that could affect the safety or pharmacokinetic evaluation of the investigational product. * Individuals with a history of hypersensitivity or clinically significant hypersensitivity reactions to losartan, pitavastatin, ezetimibe, angiotensin receptor blockers, statins, or any other medications.

Design outcomes

Primary

Measure	Time frame	Description
AUCtau,ss	Day 15	Area Under the Curve
Cmax,ss	Day 15	Maximum concentration at steady state

Secondary

Measure	Time frame	Description
Tmax,ss	Day 15	Time to maximum concentration at steady state
t1/2	Day 15	Half-life
CLss/F	Day 15	Apparent Clearance
Vdss/F	Day 15	Apparent Volume of Distribution at Steady State

Countries

South Korea

Contacts

CONTACTHuons

jywon@huons.com+82-70-7492-6023

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 11, 2026